Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of DS Healthcare Group, Inc. (NASDAQ:DSKX) investors concerning whether the company’s officers and board of directors violated the federal securities laws.

On March 23, 2016, DS Healthcare disclosed that the company’s prior financial statements should no longer be relied upon, due to revenue recognition errors and improper recording of certain equity transactions. The company has discussed these issues with its Audit Committee and independent accounting firm, and plans to restate the relevant company financial statements as soon as possible.

DS Healthcare also revealed that the Audit Committee and independent counsel had started an investigation into the involvement of the company’s President, Daniel Khesin, in the allegedly fraudulent revenue recognition and equity transaction errors; and that Mr. Khesin’s employment as President of DS Healthcare has been terminated for cause based on the current results of the investigation.

On this news, shares of DS Healthcare fell over 60% during after-hours trading on March 23, 2016, thereby injuring investors.

If you purchased DS Healthcare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.